Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas ...

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates ...

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...

The surging popularity of alternatives to Alcoholics Anonymous represents a seismic shift in the alcohol treatment landscape.

Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets ...

At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.

Tara Bannow covers hospitals, providers, and insurers. You can reach Tara on Signal at tarabannow.70. Bob Herman covers health insurance, government programs, hospitals, physicians, and other ...

Isabella is a chronic disease reporter writing about how the Trump administration is tackling the nation’s health epidemic — or not. You can reach her on Signal at isabellacueto.03. Robert F. Kennedy ...

"AI can make great strides in medical decision support, but unfiltered interaction between agent and patient is dangerous," ...

Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval ...

The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds ...